Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
112M
-
Number of holders
-
389
-
Total 13F shares, excl. options
-
80.3M
-
Shares change
-
+432K
-
Total reported value, excl. options
-
$4.26B
-
Value change
-
-$165M
-
Put/Call ratio
-
0.49
-
Number of buys
-
250
-
Number of sells
-
-168
-
Price
-
$53.01
Significant Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) as of Q2 2024
520 filings reported holding VKTX - Viking Therapeutics, Inc. - COMMON STOCK as of Q2 2024.
Viking Therapeutics, Inc. - COMMON STOCK (VKTX) has 389 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80.3M shares
of 112M outstanding shares and own 71.56% of the company stock.
Largest 10 shareholders include FMR LLC (16.5M shares), VANGUARD GROUP INC (10.1M shares), BlackRock Inc. (6.03M shares), STATE STREET CORP (5.12M shares), JPMORGAN CHASE & CO (2.25M shares), GEODE CAPITAL MANAGEMENT, LLC (1.86M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (1.4M shares), Pictet Asset Management Holding SA (1.38M shares), VIKING GLOBAL INVESTORS LP (1.35M shares), and ALLIANCEBERNSTEIN L.P. (1.24M shares).
This table shows the top 389 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.